Skip to main content
Equibles

HCG · Healthcare Global Enterprises Limited

Use HCG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HCG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
571.80 INR -3.45 (-0.60%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 3484 Avg daily vol (3M) 55.04K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close571.80 INR Open573.55 INR Day563.20–575.40 INR 52W close520.90–748.85 INR Avg vol 30d18K Last earningsNov 6, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 6
Earnings call
Q2 revenue rose 16%; oncology caps threaten mid-to-high single-digit EBITDA

HealthCare Global Enterprises Limited reported Q2 FY 2027 revenue of INR 7,318 million, up 16% year-on-year, and EBITDA of INR 1,425 million, up 17%, with a 19.7% margin. Oncology trade-margin caps could cause a mid-to-high single-digit annualized EBITDA impact.

4 source passages
Ladies and gentlemen, good day, and welcome to the HealthCare Global Enterprises Limited Earnings Conference Call. In Quarter 2 FY 2027, HCG delivered revenue of INR 7,318 million, representing a growth of 16% year- on- year. EBITDA for the quarter, including North Bengaluru loss of INR 61 million, was INR 1,425 million, representing growth of 17% year-on-year, with EBITDA margins improved to 19.7% compared to 19.2% in Q2FY26. Based on our assessment on an absolute basis, we estimate a mid-to-high single-digit percentage impact to EBITDA on an annualized basis. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲18.7% 5.58B INR 69.80M INR '25 Q3 ▲18.3% 5.85B INR 73.60M INR '25 Q4 ▲16.7% 6.13B INR 47.50M INR '26 Q1 ▲16.9% 6.47B INR 162.70M INR '26 Q2 ▲13.5% 6.33B INR −94.30M INR '26 Q3 ▲11.5% 6.52B INR 21.70M INR '26 Q4 ▲13.4% 6.95B INR 137.70M INR '27 Q1 LATEST ▲13.1% 7.32B INR 47.90M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 520.90 INR Now 571.80 INR · 22% Range high 748.85 INR
vs 200-day avg -8% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:HCG -4.8% -3.1% -12.7% -2.2% -13.7%

Exchange listing

Market
XBOM
Ticker
HCG
ISIN
INE075I01017
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.hcgoncology.com/
Investor relations
https://www.hcgoncology.com/investor-relations

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-06 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-07 Audio Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-20 Transcript
    Earnings Call for the Quarter Ended March 31, 2026